PARD (Poniard Pharmaceuticals) Cyclically Adjusted Revenue per Share: $0.00 (As of Sep. 2011)


What is Poniard Pharmaceuticals Cyclically Adjusted Revenue per Share?

Poniard Pharmaceuticals PARD Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2011.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Poniard Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2011 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2011.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-04), Poniard Pharmaceuticals's current stock price is $0.0001. Poniard Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2011 was $0.00. Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .


Poniard Pharmaceuticals  (OTCPK:PARD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Poniard Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Poniard Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Poniard Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Poniard Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2011 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2011 (Change)*Current CPI (Sep. 2011)
=0/226.8890*226.8890
=0.000

Current CPI (Sep. 2011) = 226.8890.

Poniard Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200112 12.937 176.700 16.612
200203 2.793 178.800 3.544
200206 10.982 179.900 13.850
200209 4.568 181.000 5.726
200212 80.518 180.900 100.988
200303 1.036 184.200 1.276
200306 86.356 183.700 106.659
200309 1.940 185.200 2.377
200312 0.000 184.300 0.000
200403 4.132 187.400 5.003
200406 4.000 189.700 4.784
200409 0.039 189.900 0.047
200412 0.016 190.300 0.019
200503 0.000 193.300 0.000
200506 0.014 194.500 0.016
200509 0.014 198.800 0.016
200512 0.077 196.800 0.089
200603 0.000 199.800 0.000
200606 0.000 202.900 0.000
200609 0.000 202.900 0.000
200612 0.000 201.800 0.000
200703 0.000 205.352 0.000
200706 0.000 208.352 0.000
200709 0.000 208.490 0.000
200712 0.000 210.036 0.000
200803 0.000 213.528 0.000
200806 0.000 218.815 0.000
200809 0.000 218.783 0.000
200812 0.000 210.228 0.000
200903 0.000 212.709 0.000
200906 0.000 215.693 0.000
200909 0.000 215.969 0.000
200912 0.000 215.949 0.000
201003 0.000 217.631 0.000
201006 0.000 217.965 0.000
201009 0.000 218.439 0.000
201012 0.000 219.179 0.000
201103 0.000 223.467 0.000
201106 0.000 225.722 0.000
201109 0.000 226.889 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Poniard Pharmaceuticals (PARD) has a Cyclically Adjusted Revenue per Share of $0.00 as of Sep. 2011. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Poniard Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $0.00.
How does Poniard Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to OBMP and NSPX?
Poniard Pharmaceuticals' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Cyclically Adjusted Revenue per Share is $0.00 as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.